1. COPD Management

2. This program will include a discussion of investigational agents and devices not approved by the FDA for use in the United States.

3. Introduction

4. Exacerbations and Hospital Readmissions

5. Economic Cost of COPD in the United States, 2010

6. Advances in Treatments and Guidelines

7. Recent Updates in Guidelines

8. Pharmacologic Therapies Bronchodilators

9. Pharmacologic Therapies Long-Acting Bronchodilators

10. Pharmacologic Therapies Dual Bronchodilator Therapy

11. Pharmacologic Therapies Other

12. Triple Inhaled Therapy

13. Inhaler Devices

14. pMDIs

15. DPIs

16. SMIs

17. Nebulizers

18. Long-Acting Nebulized Pharmacologic Therapy

19. Investigational Agents

20. Patient Factors to Consider for Treatment and Device Selection

21. Prevalence of COPD Among US Adults by Age Group and Sex From 2007 to 2009

22. Challenges With Proper Device Use in Older Patients With COPD

23. Techniques to Help Overcome Challenges With Proper Device Use in Patients With COPD

24. Poor Vision as a Barrier to Proper Inhaler Use

25. Teach-to-Goal Method

26. Decreased Peak Inspiratory Flow

27. Cognitive Impairment in Patients With COPD

28. Impact of Similar vs Mixed Inhaler Device Use on COPD Outcomes

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)